Aldeyra Stock Plunges as FDA Rejects Reproxalap Dry Eye Drug in Major Setback
Aldeyra Therapeutics receives FDA Complete Response Letter rejecting reproxalap for dry eye disease due to insufficient efficacy. No safety issues. ALDX shares crash.
/ 1659 items
#XY↓
Tenax Therapeutics: Cantor Sees 2x–3x Upside as First PH-HFpEF Drug Nears Pivotal Data
Cantor Fitzgerald initiates Overweight on Tenax Therapeutics with $35 target. Under-the-radar biotech nears Q3 2026 Phase 3 readout for potential first PH-HFpEF therapy — high-risk, high-reward setup.
LENSAR-Alcon Merger Terminated After FTC Block Threat; Stock Plunges
LENSAR and Alcon have mutually terminated their merger after the Federal Trade Commission threatened to block the deal.
Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost
Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.
Why HSBC Just Turned Bearish on Eli Lilly: Price Wars and Overhyped Weight-Loss Expectations
HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 from $1,070. The analyst cites an overhyped $150B+ obesity market, rising price competition, and expected cuts in 2026.
Tandem Diabetes Stock Gets a Boost: Analyst Upgrade Signals 50%+ Upside Potential
Piper Sandler upgrades Tandem Diabetes to Overweight from Neutral, raises PT to $33 from $21. Mobi pump, pharmacy pricing, and international growth drive revenue upside.